Clinical significance and predicting indicators of post‐cancer‐treatment survival in terminally ill patients with ovarian cancer

Utsumi, Fumi; Kajiyama, Hiroaki; Niimi, Keiko; Sekiya, Ryuichiro; Sakata, Jun; Suzuki, Shiro; Shibata, Kiyosumi; Mizuno, Mika; Kikkawa, Fumitaka

doi:10.1111/jog.13219

Cited by 8 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These studies were published between 1999 and 2023. Six studies were conducted in China [ 26 , 27 , 30 – 32 , 35 ], four in Japan [ 21 , 24 , 29 , 34 ], and one each in Austria [ 22 ], Australia [ 23 ], Poland [ 25 ], the USA [ 28 ], and Turkey [ 33 ]. Each of the included studies was retrospective in design and published in English [ 21 – 35 ].…”

Section: Resultsmentioning

confidence: 99%

“…Thirteen studies were single-center investigations [ 21 , 23 – 25 , 27 – 35 ], and two were multicenter trials [ 22 , 26 ]. Eleven studies included patients with OC with FIGO stages I–IV [ 21 , 22 , 24 – 27 , 30 , 32 – 35 ], three included those with FIGO stages III–IV [ 23 , 28 , 31 ], and one included OC stage IV [ 29 ]. In addition, the threshold CRP level was 3.5–70 mg/L (median, 10 mg/L).…”

Section: Resultsmentioning

confidence: 99%

“…In addition, the threshold CRP level was 3.5–70 mg/L (median, 10 mg/L). Ten studies used receiver operating characteristic (ROC) curve analysis to determine the thresholds [ 22 , 25 – 27 , 29 – 32 , 34 , 35 ], two adopted the 75th percentile value [ 21 , 28 ], and one each used values reported in the literature [ 23 ], mean value [ 24 ], and median value [ 33 ]. Fourteen articles reported the significance of CRP level in predicting OS in OC [ 21 – 33 , 35 ], while seven reported the relationship between CRP and PFS [ 24 , 25 , 27 , 31 , 32 , 34 , 35 ].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic and clinicopathological significance of C-reactive protein in patients with ovarian cancer: a meta-analysis

Zhang,

Qian

2024

World J Surg Onc

View full text Add to dashboard Cite

Background Many studies have explored the relationship between C-reactive protein (CRP) levels and survival outcomes in patients with ovarian cancer (OC); however, consistent results have not been reported. As such, this meta-analysis was performed to accurately assess the prognostic and clinicopathological roles of CRP in OC. Methods The PubMed, Web of Science, Embase, and Cochrane Library databases were systematically searched for relevant studies published from inception to April 7, 2023. The effect of CRP level(s) and OC prognostic outcomes was analyzed by computing the combined hazard ratio (HR) and corresponding 95% confidence interval (CI). Thereafter, the association between CRP level(s) and clinicopathological factors was evaluated using a combined odds ratio (OR) and corresponding 95% CI. Results The present meta-analysis included 15 studies comprising 3202 subjects. According to the combined data, higher CRP levels were markedly associated with unfavorable overall survival (OS) (HR 1.23 [95% CI 1.11–1.37]; p < 0.001) and progression-free survival (PFS) (HR 1.55 [95% CI 1.30–1.84]; p < 0.001) in patients with OC. Furthermore, the results indicated that high CRP levels were significantly correlated with International Federation of Gynecology and Obstetrics (FIGO) stages III–IV (p < 0.001), residual tumor size ≥ 1 cm (p < 0.001), histological grade 3 (p = 0.040), and ascites volume ≥ 500 mL (p < 0.001). Conclusion The results of this meta-analysis demonstrated that higher serum CRP levels were strongly associated with dismal OS and PFS in subjects with OC. High CRP levels were also significantly associated with clinical factors implicated in tumor aggressiveness and the development of OC.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic and clinicopathological significance of C-reactive protein in patients with ovarian cancer: a meta-analysis

Zhang,

Qian

2024

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…This finding is partially in concordance with our results as we also found increased white blood cell count and CA125 in patients with malignant tumors. Utsumi et al 10 reviewed 77 charts of terminally ill patients with ovarian cancer and concluded that poorer performance status, elevated white blood cell count and higher CRP value significantly correlated with shorter survival. This is partially in concordance with the results of our study, which revealed significant correlation of higher CRP and shorter overall survival.…”

Section: Discussionmentioning

confidence: 99%

The Role of Salivary and Serum Ca125 and Routine Blood Tests in Patients with Ovarian Malignancies

Vuković

Kuna

Brzak³

et al. 2021

ACC

View full text Add to dashboard Cite

The use of routine blood tests has recently been shown to be promising in determining disease-free and overall survival in patients with various malignancies, and also in gynecologic malignancies. The aim of this study was to evaluate whether salivary and serum CA125 levels correlate and whether salivary and serum CA125, C-reactive protein and routine blood tests might serve as a prognostic factor in malignant ovarian tumors, and whether they might differentiate between benign and malignant ovarian tumors. A total of 98 women were included (48 with benign ovarian tumors and 50 with malignant ovarian tumors), in whom routine blood tests were made and salivary and serum CA125 levels were determined by use of ELISA. Increase in serum CA125 and amylase decreased overall survival, whereas increase in salivary CA125, potassium levels and hemoglobin increased overall survival. Significant correlation of serum CA125 and C-reactive protein was found in the group with malignant tumors. In conclusion, significant increase in the levels of serum CA125 and amylase correlated with decreased survival, whereas increased salivary CA125, hemoglobin and potassium levels significantly correlated with increased survival.

show abstract

“…There is some contradicting evidence to suggest that chemotherapy has a role in palliation of symptoms with an apparent improvement in quality of life 37 as well as recent reports of lack of survival benefit of patients who are treated with empirically chosen chemotherapy within 3 months from their end of life. 38 When ovarian cancer progresses, goals change from cure to prolongation of life with the best possible quality for the patient. Goals of palliative chemotherapy for cancer after fourth line are mainly directed at controlling symptoms, preventing secondary burdens of toxicities, providing ease of access, limiting impact on patients' quality of time, avoid hospitalizations as far as possible, reducing economic burden of testing, and permitting access to testing at point of service.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of ChemoID® guided drug selection for palliative chemotherapy in advanced recurrent high-grade ovarian adenocarcinoma: Case study

et al. 2017

View full text Add to dashboard Cite

Notwithstanding tremendous advances in surgery, primary chemotherapy, and novel treatments for recurrent disease, the diagnosis of advanced epithelial ovarian cancer (EOC) in 2016 remains ultimately fatal in the majority of cases. Advanced therapy refractory EOC patients are often treated in hospice and with chemotherapy palliative care. The main goals of chemotherapy for recurrent/refractory ovarian cancer are the palliation of disease-related symptoms, and improvement of quality and quantity of life. Unfortunately, there is contradicting evidence suggesting that chemotherapy has a role in palliation of symptoms with an apparent improvement in quality of life. Anticancer drugs have a high rate of failure and chemotherapy response assays have been used to identify which drugs are more likely to be effective against those of gynecological origin. ChemoID® is a functional drug response assay which measures the sensitivity of cancer stem cells (CSCs) and bulk of tumor cells to chemotherapy to determine the most effective combination of anticancer drugs for solid tumors. We present a clinical case that demonstrates the utility of ChemoID® guidance to commonly available drugs with identified toxicity profiles and predictable cost profile available at POS, along with rapid response in correcting symptomatic disease features, and minimal treatment burden from toxicities. We observed in the reported case the survival and symptom management benefits of ChemoID® guided therapy even after plateau of response to cisplatin. Further studies are indicated to increase the clinical adoption of ChemoID® for gynecological malignancies in the palliative setting.

show abstract

Clinical significance and predicting indicators of post‐cancer‐treatment survival in terminally ill patients with ovarian cancer

Cited by 8 publications

References 16 publications

Prognostic and clinicopathological significance of C-reactive protein in patients with ovarian cancer: a meta-analysis

Prognostic and clinicopathological significance of C-reactive protein in patients with ovarian cancer: a meta-analysis

The Role of Salivary and Serum Ca125 and Routine Blood Tests in Patients with Ovarian Malignancies

Efficacy of ChemoID® guided drug selection for palliative chemotherapy in advanced recurrent high-grade ovarian adenocarcinoma: Case study

Contact Info

Product

Resources

About